Surgery pp 1285-1296 | Cite as

Multiple Endocrine Neoplasia

  • Terry C. Lairmore


Cancer is a genetic disease. Neoplastic transformation is characterized by a stepwise accumulation of genetic damage within a cell that results in the acquisition of increasingly more aggressive and uncontrolled growth properties. Most sporadic cancers result from the chance occurrence of multiple somatic mutations within an individual cell. Patients with one of the rare familial cancer syndromes have a predisposition to tumor development that is conferred by the inheritance of a cancer-associated mutation in the germline DNA.


Neuroendocrine Tumor Medullary Thyroid Carcinoma Multiple Endocrine Neoplasia Type Multiple Endocrine Neoplasia Familial Medullary Thyroid Carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (Lond) 1994;367:375–376.PubMedCrossRefGoogle Scholar
  2. 2.
    Blaugrund JE, Johns MM Jr, Eby YJ, et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet 1994;3:1895–1897.PubMedCrossRefGoogle Scholar
  3. 3.
    Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Gen 1997;16:375–378.CrossRefGoogle Scholar
  4. 4.
    Wells SA, Jr., Chi D, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237–250.PubMedCrossRefGoogle Scholar
  5. 5.
    Kato H, Uchimura I, Morohoshi M, et al. Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med 1996;35(4):285–289.PubMedCrossRefGoogle Scholar
  6. 6.
    Darling TN, Skarulis MC, Steinberg SM, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997;133:853–857.PubMedCrossRefGoogle Scholar
  7. 7.
    Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975;72:5116–5120.PubMedCrossRefGoogle Scholar
  8. 8.
    Doherty GM, Lairmore TC, DeBenedetti MK. Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg 2004;28(11):1139–1142.PubMedCrossRefGoogle Scholar
  9. 9.
    Bassett JHD, Forbes SA, Pannett AAJ, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232–244.PubMedCrossRefGoogle Scholar
  10. 10.
    Lairmore TC, Piersall LD, DeBenedetti MK, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 2004;239(5):637–645; discussion 645–647.PubMedCrossRefGoogle Scholar
  11. 11.
    Marx SJ, Menczel J, Campbell S, et al. Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1. Clin Endocrinol 1991;35:521–526.CrossRefGoogle Scholar
  12. 12.
    Majewski JT, Wilson SD. The MEA-I syndrome: An all or none phenomenon. Surgery (St. Louis) 1979;86:475–484.PubMedGoogle Scholar
  13. 13.
    Wilkinson S, Teh BT, Davey KR, et al. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993;128:683.PubMedGoogle Scholar
  14. 14.
    Doherty GM, Olson JA, Frisella MM, et al. Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22(6):581–586; discussion 586–587.PubMedCrossRefGoogle Scholar
  15. 15.
    Stabile BE, Morrow DJ, Passaro EJ. The gastrinoma triangle: operative indications. Am J Surg 1984;147:25–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. Ann Surg 1989;209:396–404.PubMedCrossRefGoogle Scholar
  17. 17.
    Delcore RJ, Cheung LY, Friesen SR. Characteristics of duodenal wall gastrinomas. Am J Surg 1990;160:621–624.PubMedCrossRefGoogle Scholar
  18. 18.
    Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10 year prospective study. Ann Surg 1992;215:8–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Friesen SR. Are “aberrant nodal gastrinomas” pathogenetically similar to “lateral aberrant thyroid” nodules? Surgery (St. Louis) 1990;107:236–238.PubMedGoogle Scholar
  20. 20.
    Wolfe MM, Alexander RW, McGuigan JE. Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery. N Engl J Med 1982;306:1533–1536.PubMedGoogle Scholar
  21. 21.
    Delcore RJ, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with Zollinger-Ellison syndrome. Ann Surg 1988;206:291–298.Google Scholar
  22. 22.
    Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003;237(5):650–657; discussion 657–659.PubMedCrossRefGoogle Scholar
  23. 23.
    Friesen SR. Treatment of the Zollinger-Ellison syndrome. Am J Surg 1982;143:331–338.PubMedCrossRefGoogle Scholar
  24. 24.
    Cameron AJ, Hoffman HN. Zollinger-Ellison syndrome: clinical features and long-term follow-up. Mayo Clin Proc 1974;49:44–51.PubMedGoogle Scholar
  25. 25.
    Bondeson AG, Bondeson L, Thompson NW. Stricture and perforation of the esophagus: overlooked threats in Zollinger-Ellison syndrome. World J Surg 1990;14:361–364.PubMedCrossRefGoogle Scholar
  26. 26.
    Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990;98:341–346.PubMedGoogle Scholar
  27. 27.
    Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994;31:77–156.PubMedCrossRefGoogle Scholar
  28. 28.
    Doppman JL, Miller DL, Chang R, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 1990;174:25–29.PubMedGoogle Scholar
  29. 29.
    van Heerden JA, Smith SL, Miller LJ. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type I. Surgery (St. Louis) 1986;100:971–977.PubMedGoogle Scholar
  30. 30.
    Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and management. N Engl J Med 1987;317:1200–1209.PubMedGoogle Scholar
  31. 31.
    Sheppard BC, Norton JA, Doppman JL, et al. Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery (St. Louis) 1989;106:1108–1118.PubMedGoogle Scholar
  32. 32.
    Weber HC, Verizon DJ, Lin J-T, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995;108:1637–1649.PubMedCrossRefGoogle Scholar
  33. 33.
    Lowney JK, Frisella MM, Lairmore TC, Doherty GM. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery (St. Louis) 1998;124:1043–1049.PubMedCrossRefGoogle Scholar
  34. 34.
    Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery (St. Louis) 2004;136(6):1267–1274.PubMedCrossRefGoogle Scholar
  35. 35.
    Norton JA, Fraker DL, Alexander R, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999;341:635–644.PubMedCrossRefGoogle Scholar
  36. 36.
    Norton JA, Alexander HR, Fraker DL, et al. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004;239(5):617–625; discussion 626.PubMedCrossRefGoogle Scholar
  37. 37.
    Doppman JL, Miller DL, Chang R, et al. Insulinomas: localization with selective intraarterial injection of calcium. Radiology 1991;178:237–241.PubMedGoogle Scholar
  38. 38.
    Cohen MS, Picus D, Lairmore TC, et al. Prospective study of provocative angiograms to localize functional islet cell tumors of the pancreas. Surgery (St. Louis) 1997;122:1091–1100.PubMedCrossRefGoogle Scholar
  39. 39.
    Grant CS, van Heerden J, Charboneau JW, et al. Insulinoma: the value of intraoperative ultrasonography. Arch Surg 1988;123:843–848.PubMedGoogle Scholar
  40. 40.
    Norton JA, Cromack DT, Shawker TH, et al. Intraoperative ultrasonographic localization of islet cell tumors. Ann Surg 1988;207:160–168.PubMedCrossRefGoogle Scholar
  41. 41.
    Doherty GM, Doppman JL, Shawker TH, et al. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery (St. Louis) 1991;110:989–996.PubMedGoogle Scholar
  42. 42.
    Marx S, Spiegel AM, Skarulis MC, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129:484–494.PubMedGoogle Scholar
  43. 43.
    Duh Q-Y. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987;154:142–148.PubMedCrossRefGoogle Scholar
  44. 44.
    Chandrasekharappa SC, Guru SC, Manickamp P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404–407.PubMedCrossRefGoogle Scholar
  45. 45.
    Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A 1998;95:1630–1634.PubMedCrossRefGoogle Scholar
  46. 46.
    Mutch MG, Dilley WG, Sanjurjo F, et al. Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. Hum Mutat 1999;13(3):175–185.PubMedCrossRefGoogle Scholar
  47. 47.
    Olufemi SE, Green JS, Manickam P, et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN 1 (MEN1 Burin) in four kindreds from Newfoundland. Hum Mutat 1998;11:264–269.PubMedCrossRefGoogle Scholar
  48. 48.
    Kassem M, Kruse TA, Wong FK, et al. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 2000;85:165–167.PubMedCrossRefGoogle Scholar
  49. 49.
    Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the API transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143–152.PubMedCrossRefGoogle Scholar
  50. 50.
    Gobi AE, Berg M, Lopez-Egido JR, et al. Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1999;1447(1):51–56.Google Scholar
  51. 51.
    Lemmens IH, Forsberg L, Pannett AA, et al. Menin interacts directly with the homeobox-containing protein Pern. Biochem Biophys Res Commun 2001;286(2):426–431.PubMedCrossRefGoogle Scholar
  52. 52.
    Heppner C, Bilimoria KY, Agarwal SK, et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001;20(36):4917–4925.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaji H, Canaff L, Lebrun JJ, et al. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A 2001;98(7):3837–3842.PubMedCrossRefGoogle Scholar
  54. 54.
    Ohkura N, Kishi M, Tsukada T, Yamaguchi K. Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis protein nm23. Biochim Biophys Res Commun 2001;282(5):1206–1210.CrossRefGoogle Scholar
  55. 55.
    Rizzoli R, Green J, Marx SJ. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 1985;78:467–473.PubMedCrossRefGoogle Scholar
  56. 56.
    Wells SA Jr, Farndon JR, Dale JK, et al. Long term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 1980;192:451–458.PubMedGoogle Scholar
  57. 57.
    Hellman P, Skogseid B, Juhlin C, et al. Findings and long term results of parathyroid surgery in multiple endocrine neoplasia type 1. World J Surg 1992;16:718–723.PubMedCrossRefGoogle Scholar
  58. 58.
    Kraimps JL, Duh Q-Y, Demeure M, Clark OH. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery (St. Louis) 1992;112:1080–1088.PubMedGoogle Scholar
  59. 59.
    van Heerden JA, Kent RB, Sizemore GW, et al. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes: surgical experience. Arch Surg 1983;118:533–536.PubMedGoogle Scholar
  60. 60.
    Elaraj DM, Skarulis MC, Libutti SK, et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery (St. Louis) 2003;134(6):858–864; discussion 864–865.PubMedCrossRefGoogle Scholar
  61. 61.
    Lairmore TC, Chen VY, DeBenedetti MK, et al. Duodenopancre-atic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231:909–918.PubMedCrossRefGoogle Scholar
  62. 62.
    Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984;8:561–574.PubMedCrossRefGoogle Scholar
  63. 63.
    Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991;73:281–287.PubMedGoogle Scholar
  64. 64.
    Skogseid B, Grama D, Rastad J, et al. Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1. J Intern Med 1995;238:281–288.PubMedGoogle Scholar
  65. 65.
    Skogseid B, Öberg K. Experience with multiple endocrine neoplasia type 1 screening. J Intern Med 1995;238:255–261.PubMedGoogle Scholar
  66. 66.
    Doppman JL. Multiple endocrine neoplasia syndromes. A nightmare for the endocrinologic radiologist. Semin Roentgenol 1985;20:7–16.PubMedCrossRefGoogle Scholar
  67. 67.
    Skogseid B, Oberg K, Benson L, et al. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: Five years experience. J Clin Endocrinol Metab 1987;64:1233–1240.PubMedGoogle Scholar
  68. 68.
    Lairmore TC. Complications in endocrine pancreatic surgery. In: Mulholland M, Doherty G, eds. Complications in Surgery. Philadelphia: Lippincott Williams & Wilkins, 2005.Google Scholar
  69. 69.
    Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961;31:163–166.CrossRefGoogle Scholar
  70. 70.
    Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia type 2. Medicine (Baltim) 1968;47:371–409.PubMedCrossRefGoogle Scholar
  71. 71.
    Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery (St. Louis) 1993;114:1070–1077.PubMedGoogle Scholar
  72. 72.
    Williams ED, Pollack DJ. Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen’s disease. J Pathol Bacteriol 1966;91:71–80.PubMedCrossRefGoogle Scholar
  73. 73.
    Schimke RN, Hartmann WH, Prout TE, Rimoin DL. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. N Engl J Med 1968;279:1–7.PubMedGoogle Scholar
  74. 74.
    Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278–281.PubMedCrossRefGoogle Scholar
  75. 75.
    Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature (Lond) 1996;381:785–789.PubMedCrossRefGoogle Scholar
  76. 76.
    Durbec P, Macos-Gutierrez CV, Kilkenny C, et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature (Lond) 1996;381:789–793.PubMedCrossRefGoogle Scholar
  77. 77.
    Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell 1996;85:1113–1124.PubMedCrossRefGoogle Scholar
  78. 78.
    Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development (Cambr) 1993;119:1005–1017.PubMedGoogle Scholar
  79. 79.
    Avantaggiato V, Dathan NA, Grieco M, et al. Developmental expression of the RET protooncogene. Cell Growth Differ 1994;5:305–311.PubMedGoogle Scholar
  80. 80.
    Schuchardt A, D’Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature (Lond) 1994;367:380–383.PubMedCrossRefGoogle Scholar
  81. 81.
    Edery P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature (Lond) 1994;367:378–380.PubMedCrossRefGoogle Scholar
  82. 82.
    Romeo G, Ronchetto P, Luo Y, et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung’s disease. Nature (Lond) 1994;367:377–378.PubMedCrossRefGoogle Scholar
  83. 83.
    Pasini B, Borrello MG, Greco A, et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 1995;10:35–40.PubMedCrossRefGoogle Scholar
  84. 84.
    Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominantly transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381–383.PubMedCrossRefGoogle Scholar
  85. 85.
    Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994;6:70–74.PubMedCrossRefGoogle Scholar
  86. 86.
    Herfarth KK-F, Bartsch D, Doherty GM, et al. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery (St. Louis) 1996;120:966–974.PubMedCrossRefGoogle Scholar
  87. 87.
    Carlson KM, Dou S, Chi D, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 1994;91:1579–1583.PubMedCrossRefGoogle Scholar
  88. 88.
    Smith DP, Houghton C, Ponder BAJ. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 1997;15:1213–1217.PubMedCrossRefGoogle Scholar
  89. 89.
    Carlson KM, Bracamontes J, Jackson CE, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994;55:1076–1082.PubMedGoogle Scholar
  90. 90.
    Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509–513.PubMedGoogle Scholar
  91. 91.
    Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10:2415–2419.PubMedGoogle Scholar
  92. 92.
    Tashjian AH Jr, Howland BG, Melvin KEW, Hill CS Jr. Immunoassay of human calcitonin: clinical measurement, relation to serum calcium and studies in patients with medullary carcinoma. N Engl J Med 1970;283:890–895.CrossRefGoogle Scholar
  93. 93.
    Wells SA Jr, Baylin SB, Linehan WM, et al. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978;188:139–141.PubMedCrossRefGoogle Scholar
  94. 94.
    Wells SA, Jr., Baylin SB, Leight GS, et al. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 1982;195:595–599.PubMedCrossRefGoogle Scholar
  95. 95.
    Gottlieb JA, Hill CS. Chemotherapy of thyroid cancer with Adriamycin. N Engl J Med 1974;290:193–197.PubMedCrossRefGoogle Scholar
  96. 96.
    Steinfeld AD. The role of radiation therapy in medullary carcinoma of the thyroid. Radiology 1977;123:745–746.PubMedGoogle Scholar
  97. 97.
    Tubiani M. External radiotherapy and radioiodine in the treatment of thyroid cancer. World J Surg 1981;1981:75–84.CrossRefGoogle Scholar
  98. 98.
    Lips CJM, Landsvater RM, Höppener JWM, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828–835.PubMedCrossRefGoogle Scholar
  99. 99.
    Skinner MA, DeBenedetti MK, Moley JF, et al. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996;31:177–182.PubMedCrossRefGoogle Scholar
  100. 100.
    Lairmore TC, Frisella MM, Wells SA Jr. Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Ann Med 1996;28(5):401–406.PubMedCrossRefGoogle Scholar
  101. 101.
    Lairmore TC, Frisella MM, Wells SAJ. Genetic testing and early thyroidectomy for inherited medullary thyroid carcinoma. Ann Med 1996;28:401–406.PubMedCrossRefGoogle Scholar
  102. 102.
    Skinner MA, Moley JF, Dilley WG, Owzar K, DeBenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. NEJM 2005;353:1105–1113.PubMedCrossRefGoogle Scholar
  103. 103.
    Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999;229(6):880–887; discussion 887–888.PubMedCrossRefGoogle Scholar
  104. 104.
    Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997;225:734–743.PubMedCrossRefGoogle Scholar
  105. 105.
    Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery (St. Louis) 1986;99:60–66.PubMedGoogle Scholar
  106. 106.
    Carney JA, Sizemore GW, Tyce GM. Bilateral adrenal medullary hyperplasia in multiple endocrine neoplasia, type 2: the precursor of bilateral pheochromocytoma. Mayo Clin Proc 1975;50:3–10.PubMedGoogle Scholar
  107. 107.
    Carney JA, Sizemore GW, Sheps SG. Adrenal medullary disease in multiple endocrine neoplasia, type 2: pheochromocytoma and its precursors. Am J Clin Pathol 1976;66:279–290.PubMedGoogle Scholar
  108. 108.
    Freier DT, Thompson NW, Sisson JC, et al. Dilemmas in the early diagnosis and treatment of multiple endocrine adenomatosis, type II. Surgery (St. Louis) 1977;82:407–413.PubMedGoogle Scholar
  109. 109.
    Lips KJM, van der Sluys Veer J, Struyvenberg A, et al. Bilateral occurrence of pheochromocytoma in patients with the multiple endocrine neoplasia syndrome type 2A (Sipple’s syndrome). Am J Med 1981;70:1051–1060.PubMedCrossRefGoogle Scholar
  110. 110.
    van Heerden JA, Sizemore GW, Carney JA, et al. Surgical management of the adrenal glands in the multiple endocrine neoplasia type II syndrome. World J Surg 1984;8:612–621.PubMedCrossRefGoogle Scholar
  111. 111.
    Tibblin S, Dymling J-F, Ingemansson S, Telenius-Berg M. Unilateral versus bilateral adrenalectomy in multiple endocrine neoplasia HA. World J Surg 1983;7:201–208.PubMedCrossRefGoogle Scholar
  112. 112.
    Lairmore TC, Ball DW, Baylin SB, Wells SA Jr. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993;217:595–603.PubMedCrossRefGoogle Scholar
  113. 113.
    Gagner M, Lacroix A, Prinz RA, et al. Early experience with laparoscopic approach for adrenalectomy. Surgery (St. Louis) 1993;114:1120–1125.PubMedGoogle Scholar
  114. 114.
    Gagner M, Lacroix A, Bolte E, Pomp A. Laparoscopic adrenalectomy: the importance of a flank approach in the lateral decubitus position. Surg Endosc 1994;8:135–138.PubMedCrossRefGoogle Scholar
  115. 115.
    Lepsien G, Neufang T, Ludtke FE. Laparoscopic resection of pheochromocytoma. Surg Endosc 1994;8:906–909.PubMedCrossRefGoogle Scholar
  116. 116.
    Brunt LM, Doherty GM, Norton JA, et al. Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms. J Am Coll Surg 1996;183:1–10.PubMedGoogle Scholar
  117. 117.
    Brunt LM, Lairmore TC, Doherty GM, et al. Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg 2002;235(5):713–720; discussion 720–721.PubMedCrossRefGoogle Scholar
  118. 118.
    Guazzoni G, Montorsi F, Bocciardi A, et al. Transperitoneal laparoscopic versus open adrenalectomy for benign hyperfunctioning adrenal tumors. J Urol 1995;153:1597–1600.PubMedCrossRefGoogle Scholar
  119. 119.
    Prinz RA. A comparison of laparoscopic and open adrenalectomies. Arch Surg 1995;130:489–494.PubMedGoogle Scholar
  120. 120.
    O’Riordain DS, O’Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery (St. Louis) 1993;114:1031–1039.PubMedGoogle Scholar
  121. 121.
    Raue F, Kraimps JL, Dralle H, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 1995;238:369–373.PubMedCrossRefGoogle Scholar
  122. 122.
    Phan GQ, Yeo CJ, Cameron JL, et al. Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. Surgery (St. Louis) 1997;122:989–997.PubMedCrossRefGoogle Scholar
  123. 123.
    Park BJ, Alexander R, Libutti SK, et al. Operative management of islet cell tumors arising in the head of the pancreas. Surgery (St. Louis) 1998;124:1056–1062.PubMedCrossRefGoogle Scholar
  124. 124.
    Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001;15(10):1653–1664.PubMedCrossRefGoogle Scholar
  125. 125.
    Lairmore TC, Moley JF. The multiple endocrine neoplasia syndromes. In: Townsend CM, Beauchamp DR, Evers BM, Mattox KL eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 17th ed. Philadelphia: Saunders, 2004;1071–1087.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Terry C. Lairmore
    • 1
  1. 1.Division of Surgical Oncology, Scott and White Memorial Hospital and ClinicTexas A&M University System Health Science CenterTempleUSA

Personalised recommendations